FDA cleared Otarmeni, giving Regeneron the first-ever approval for a gene therapy to treat a rare type of inherited hearing loss.
The approval is a milestone for the field. Gene therapy for inherited hearing loss has been a stated goal for over a decade, with the complexity of the inner ear and regulatory uncertainty slowing development. Today’s clearance shows FDA will back these interventions when the clinical evidence supports it.
That’s the signal the rest of the pipeline needed. A first-in-class approval doesn’t just clear a regulatory hurdle; it shows the clinical bar is climbable.
The precedent is what makes this consequential. Every sponsor running a hearing-related gene therapy program now has a cleared regulatory pathway to reference. Timelines get revised. Investor conversations shift. Competitors with programs in adjacent inherited hearing conditions now face a race with a known finish line.
For patients with this specific rare inherited condition, Otarmeni is the first treatment that addresses genetic cause rather than compensating for function. Hearing aids and cochlear implants can help with the loss; they don’t go after the mutation.
— Sarah Chen